Abstract: Powder formulations for inhalation which comprise microparticles containing an antibiotic and magnesium stearate are useful for the treatment of bacterial infections associated with certain pulmonary diseases.
Abstract: Dry powder formulations for inhalation comprising a combination of an anti-cholinergic, a long-acting beta2-adrenoceptor agonist, and, optionally, an inhaled corticosteroid are useful for the prevention and/or treatment of an inflammatory and/or obstructive airways disease.
Abstract: Stable aerosol solution formulations comprising glycopyrronium bromide are useful for administration to patients with COPD and other respiratory conditions.
Abstract: A process for preparing a dry powder formulation for inhalation comprising a combination of an anti-cholinergic, a long-acting beta2-adrenoceptor agonist, and a corticosteroid is provided.
Abstract: Dry powder formulations for inhalation comprising a combination of an anticholinergic, a long-acting beta2-adrenoceptor agonist, and, optionally, an inhaled corticosteroid are useful for the prevention and/or treatment of an inflammatory and/or obstructive airways disease.
Abstract: The invention is directed to pharmaceutical compositions such as tablets that exhibit delayed release properties when administered as either whole or half tablets. The invention is also directed to delayed release tablets comprising deferiprone for oral administration, for which twice daily administration is bioequivalent to the same daily dose of an immediate release tablet administered thrice daily. The invention is also directed to methods of making and using the same.
Abstract: System comprising a pre-fillable syringe with a syringe barrel and a syringe tip and a package suitable and intended for receiving the pre-fillable syringe, wherein the syringe tip is provided with a tip cap, wherein the system comprises a replacement cap for the pre-fillable syringe, wherein the package is suitable and intended for receiving the replacement cap.
Type:
Application
Filed:
March 11, 2020
Publication date:
September 17, 2020
Applicant:
Chiesi Farmaceutici S.p.A.
Inventors:
Jurgen Pfrang, Andreas Gorshofer, Marta Lombardini
Abstract: System comprising a pre-fillable syringe with a syringe barrel and a syringe tip and a package suitable and intended for receiving the pre-fillable syringe, wherein the syringe tip is provided with a tip cap, wherein the system comprises a replacement cap for the pre-fillable syringe, wherein the package is suitable and intended for receiving the replacement cap.
Type:
Application
Filed:
March 15, 2019
Publication date:
September 17, 2020
Applicant:
Chiesi Farmaceutici S.p.A.
Inventors:
Jurgen PFRANG, Andreas GORSHOFER, Marta LOMBARDINI
Abstract: Dry powder formulations for inhalation containing a combination of an anti-cholinergic, a long-acting beta2-adrenoceptor agonist, and a corticosteroid are useful for the prevention and/or treatment of an inflammatory and/or obstructive airways disease.
Abstract: The present invention relates to a process for the preparation of compounds endowed with phosphodiesterase (PDE4) inhibitory activity having formula (I). The invention also relates to the process for the isolation by crystallization of the compound (I) and to its use for the preparation of pharmaceutical compositions for inhalation in combination with suitable carriers or vehicles. The present invention also relates to solvates and crystal forms of a compound of formula (I). The synthesized product is suitable for use in pharmaceutical applications for instance in the treatment of respiratory diseases.
Abstract: A method for reducing or maintaining platelet inhibition in a patient by administering cangrelor prior to an invasive procedure is described. The method of this invention can be used for patients in need of antiplatelet therapy or at risk of thrombosis. The method can further be used in patients who were previously treated with long-acting platelet inhibitors without increasing the risk of excessive bleeding.
Type:
Grant
Filed:
March 18, 2019
Date of Patent:
August 18, 2020
Assignee:
Chiesi Farmaceutici S.p.A.
Inventors:
Lisa Ruderman Chen, Simona Skerjanec, Dawn Bell, Jayne Prats, Meredith Todd
Abstract: Actuators for an aerosol inhalation device containing a housing adapted to receive an aerosol canister containing a pressurized medicament formulation, a mouthpiece portion through which the user inhales, a nozzle block and an orifice and a tubular element extending in the mouthpiece portion from the orifice aperture in a longitudinal axis substantially aligned with a longitudinal axis of the mouthpiece portion provide a significant reduction in the non-respirable, coarse fraction of the emitted aerosol medicament via inertial impaction and retention in the actuator than in the oro-pharynx, with consequent less associated side effects and oral candidiasis in the patient. In addition the presence of the tubular element has minimal, negligible impact on the fine particle dose and on the particle size distribution (PSD) of the delivered particles having aerodynamic diameter lower than 9 ?m.
Type:
Grant
Filed:
September 26, 2016
Date of Patent:
August 11, 2020
Assignee:
CHIESI FARMACEUTICI S.p.A.
Inventors:
Gaetano Brambilla, Robert Johnson, David Andrew Lewis
Abstract: Administering a pulmonary surfactant and a corticosteroid is effective for the treatment of evolving bronchopulmonary dysplasia (BPD) in preterm neonates.
Abstract: Formulation comprising buprenorphine or a pharmaceutically acceptable salt thereof as the sole active ingredient, a viscosity enhancer, and a buffering agent in an amount to provide a pH of from 5.0 to 7.0 are useful for treating opioid withdrawal syndrome.
Type:
Application
Filed:
April 16, 2020
Publication date:
July 30, 2020
Applicant:
CHIESI FARMACEUTICI S.p.A.
Inventors:
Grazia CAIVANO, Ana Filipa SILVA BORGES
Abstract: Carrier particles in the form of granules described herein are suitable for use in dry powder formulations for inhalation, and preferably administering high-strength dose active ingredients.
Abstract: Administering a pulmonary surfactant and a corticosteroid is effective for the treatment of evolving bronchopulmonary dysplasia (BPD) in preterm neonates.
Abstract: Carrier particles in the form of granules described herein are suitable for use in dry powder formulations for inhalation, and preferably administering high-strength dose active ingredients.
Abstract: Formulation comprising buprenorphine or a pharmaceutically acceptable salt thereof as the sole active ingredient, a viscosity enhancer, and a buffering agent in an amount to provide a pH of from 5.0 to 7.0 are useful for treating opioid withdrawal syndrome.
Type:
Grant
Filed:
October 18, 2018
Date of Patent:
May 26, 2020
Assignee:
CHIESI FARMACEUTICI S.p.A.
Inventors:
Grazia Caivano, Ana Filipa Silva Borges
Abstract: The present invention relates to methods for lowering stroke damages and/or lowering blood pressure in a subject with a stroke in need thereof, comprising administering to the subject an effective amount of a pharmaceutical composition comprising a short acting dihydropyridine compound, preferably clevidipine or a pharmaceutically acceptable salt or ester thereof. Also provided are related medicaments, pharmaceutical compositions, and methods for preparing the medicaments.